438 related articles for article (PubMed ID: 30539465)
21. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
Kareva I
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
[TBL] [Abstract][Full Text] [Related]
22. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
23. [Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures].
Larbouret C; Poul MA; Chardès T
Med Sci (Paris); 2019 Dec; 35(12):1083-1091. PubMed ID: 31903921
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Teige I; Mårtensson L; Frendéus BL
Front Immunol; 2019; 10():481. PubMed ID: 30930905
[TBL] [Abstract][Full Text] [Related]
25. The use of ofatumumab in the treatment of B-cell malignancies.
Soe ZN; Allsup D
Future Oncol; 2017 Dec; 13(29):2611-2628. PubMed ID: 28850252
[TBL] [Abstract][Full Text] [Related]
26. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
Diesendruck Y; Benhar I
Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
[TBL] [Abstract][Full Text] [Related]
27. Neoantigens in the immuno-oncology space.
Arlen PM
Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
[No Abstract] [Full Text] [Related]
28. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
Shivarov V; Blazhev G
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
Tsao LC; Force J; Hartman ZC
Cancer Res; 2021 Sep; 81(18):4641-4651. PubMed ID: 34145037
[TBL] [Abstract][Full Text] [Related]
30. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
31. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large B-cell lymphoma: new targets and novel therapies.
Cheson BD; Nowakowski G; Salles G
Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
[TBL] [Abstract][Full Text] [Related]
33. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab.
Ku M; Chong G; Hawkes EA
Blood Rev; 2017 Jan; 31(1):23-35. PubMed ID: 27568879
[TBL] [Abstract][Full Text] [Related]
34. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
35. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
36. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of the PD-1 Pathway in Tumor Therapy.
LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies.
Bhandaru M; Rotte A
Methods Mol Biol; 2019; 1904():83-108. PubMed ID: 30539467
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
Shevchenko I; Bazhin AV
Front Immunol; 2018; 9():1816. PubMed ID: 30131808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
